{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T11:07:47Z","timestamp":1794481667221,"version":"4.9.1"},"publisher-location":"Berlin, Heidelberg","reference-count":29,"publisher":"Springer Berlin Heidelberg","isbn-type":[{"value":"9783662445778","type":"print"},{"value":"9783662445785","type":"electronic"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014]]},"DOI":"10.1007\/8904_2014_328","type":"book-chapter","created":{"date-parts":[[2014,7,25]],"date-time":"2014-07-25T10:33:04Z","timestamp":1406284384000},"page":"29-36","source":"Crossref","is-referenced-by-count":9,"title":["Antiepileptic Medications Increase Osteoporosis Risk in Male Fabry Patients: Bone Mineral Density in an Australian Cohort"],"prefix":"10.1007","author":[{"given":"Andrew","family":"Talbot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna R.","family":"Ghali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Nicholls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,7,26]]},"reference":[{"key":"328_CR1","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.ejrad.2008.04.062","volume":"71","author":"GM Blake","year":"2009","unstructured":"Blake GM, Fogelman I (2009) The clinical role of dual energy X-ray absorptiometry. Eur J Radiol 71:406\u2013414","journal-title":"Eur J Radiol"},{"key":"328_CR2","doi-asserted-by":"publisher","first-page":"338","DOI":"10.7326\/0003-4819-138-4-200302180-00014","volume":"138","author":"RJ Desnick","year":"2003","unstructured":"Desnick RJ, Brady R, Barranger J et al (2003) Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med 138:338\u2013346","journal-title":"Ann Intern Med"},{"key":"328_CR3","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1210\/jc.2011-3058","volume":"97","author":"MT Drake","year":"2012","unstructured":"Drake MT, Murad MH, Mauck KF et al (2012) Risk factors for low bone mass-related fractures in men: a systematic review and meta-analysis. J Clin Endocr Metab 97:1861\u20131870","journal-title":"J Clin Endocr Metab"},{"key":"328_CR4","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1056\/NEJMcp0707217","volume":"358","author":"P Ebeling","year":"2008","unstructured":"Ebeling P (2008) Osteoporosis in men. New Engl J Med 358:1474\u20131482","journal-title":"New Engl J Med"},{"key":"328_CR5","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1007\/s00198-012-2030-x","volume":"23","author":"S Ferrari","year":"2012","unstructured":"Ferrari S, Bianchi ML, Eisman JA et al (2012) Osteoporosis in young adults: pathophysiology, diagnosis, and management. Osteoporosis Int 23:2735\u20132748","journal-title":"Osteoporosis Int"},{"key":"328_CR6","unstructured":"Germain DP (2010) Bone and muscle involvement in fabry disease. In: Elstein D, Altarecu G, Beck M (eds) Fabry disease. Chap 16, pp 293\u2013298"},{"key":"328_CR7","doi-asserted-by":"crossref","unstructured":"Germain DP (2010) Fabry disease. Orphanet J Rare Dis 5:30","DOI":"10.1186\/1750-1172-5-30"},{"key":"328_CR8","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/j.1399-0004.2005.00457.x","volume":"68","author":"DP Germain","year":"2005","unstructured":"Germain DP, Benistan K, Boutouyrie P, Mutschler C (2005) Osteopenia and osteoporosis: previously unrecognized manifestations of Fabry disease. Clin Genet 68:93\u201395","journal-title":"Clin Genet"},{"key":"328_CR9","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1111\/j.1742-1241.2005.00620.x","volume":"59","author":"AC Hauser","year":"2005","unstructured":"Hauser AC, Gessl A, Harm F et al (2005) Hormonal profile and fertility in patients with Anderson\u2013Fabry disease. Int J Clin Pract 59:1025\u20131028","journal-title":"Int J Clin Pract"},{"key":"328_CR10","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1530\/EJE-10-0015","volume":"162","author":"LC Hofbauer","year":"2010","unstructured":"Hofbauer LC, Hamann C, Ebeling PR (2010) Approach to the patient with secondary osteoporosis. Eur J Endocrinol 162:1009\u20131020","journal-title":"Eur J Endocrinol"},{"key":"328_CR11","unstructured":"International Society of Clinical Densitometry (ISCD) (2013) Official positions of the International Society of Clinical Densitometry: updated 2013. www.iscd.org\/official-positions\/2013-iscd-official-positions-adult\/"},{"key":"328_CR12","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1592\/phco.30.3.254","volume":"30","author":"JE Isenor","year":"2010","unstructured":"Isenor JE, Ensom MH (2010) Is there a role for therapeutic drug monitoring of vitamin D level as a surrogate marker for fracture risk? Pharmacotherapy 30:254\u2013264","journal-title":"Pharmacotherapy"},{"key":"328_CR13","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1359\/JBMR.050304","volume":"20","author":"O Johnell","year":"2005","unstructured":"Johnell O, Kanis JA, Oden A et al (2005) Predictive value of BMD for hip and other fractures. J Bone Miner Res 20:1185\u20131194","journal-title":"J Bone Miner Res"},{"key":"328_CR14","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1007\/BF01622200","volume":"4","author":"JA Kanis","year":"1994","unstructured":"Kanis JA (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporosis Int 4:368\u2013381","journal-title":"Osteoporosis Int"},{"key":"328_CR15","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1007\/s00198-011-1632-z","volume":"22","author":"JA Kanis","year":"2011","unstructured":"Kanis JA, Bianchi G, Bilezikian P et al (2011) Towards a diagnostic consensus in male osteoporosis. Osteoporosis Int 22:2789\u20132798","journal-title":"Osteoporosis Int"},{"key":"328_CR16","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1111\/j.1365-2265.2009.03701.x","volume":"73","author":"P Lips","year":"2010","unstructured":"Lips P, Bouillon R, van Schoor NM et al (2010) Reducing fracture risk with calcium and vitamin D. Clin Endocrinol 73:277\u2013285","journal-title":"Clin Endocrinol"},{"key":"328_CR17","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1136\/bmj.312.7041.1254","volume":"312","author":"D Marshall","year":"1996","unstructured":"Marshall D, Johnell O, Wedel H (1996) Meta-analysis of how well measures of bone density predict occurrence of osteoporotic fracture. Brit Med J 312:1254\u20131259","journal-title":"Brit Med J"},{"key":"328_CR18","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1136\/jmg.2008.065904","volume":"46","author":"A Mehta","year":"2009","unstructured":"Mehta A, Clarke JTR, Giugliani R, on behalf of the FOS Investigators et al (2009) Natural course of Fabry disease: changing pattern of causes of death in FOS \u2013 Fabry Outcome Survey. J Med Genet 46:548\u2013552","journal-title":"J Med Genet"},{"key":"328_CR19","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1097\/GIM.0b013e31815cb197","volume":"9","author":"H Mersebach","year":"2007","unstructured":"Mersebach H, Johansson J-O, Rasmussen A et al (2007) Osteopenia: a common aspect of Fabry disease. Predictors of bone mineral density. Genet Med 9:812\u2013818","journal-title":"Genet Med"},{"key":"328_CR20","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s12020-012-9813-x","volume":"43","author":"T Montalcini","year":"2013","unstructured":"Montalcini T, Romeo S, Ferro Y, Migliaccio V, Gazzaruso C, Pujia A (2013) Osteoporosis in chronic inflammatory disease; the role of malnutrition. Endocrine 43:59\u201364","journal-title":"Endocrine"},{"key":"328_CR21","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1517\/14740331003636475","volume":"9","author":"KO Nakken","year":"2010","unstructured":"Nakken KO, Taub\u00f8ll E (2010) Bone loss associated with use of antiepileptic drugs. Expert Opin Drug Saf 9:561\u2013571","journal-title":"Expert Opin Drug Saf"},{"key":"328_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00774-012-0392-y","volume":"31","author":"Y Nishizawa","year":"2013","unstructured":"Nishizawa Y, Ohta H, Miura M et al (2013) Guidelines for the use of bone metabolic markers in the diagnosis and treatment of osteoporosis (2012 edition). J Bone Miner Metab 31:1\u201315","journal-title":"J Bone Miner Metab"},{"key":"328_CR23","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.yebeh.2011.02.009","volume":"22","author":"AM Pack","year":"2011","unstructured":"Pack AM, Reddy DS, Duncan S, Herzog A (2011) Neuroendocrinological aspects of epilepsy: Important issues and trends in future research. Epilepsy Behav 22:94\u2013102","journal-title":"Epilepsy Behav"},{"key":"328_CR24","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s00198-006-0185-z","volume":"18","author":"SJ Petty","year":"2007","unstructured":"Petty SJ, O\u2019Brien TJ, Wark JD (2007) Anti-epileptic medication and bone health. Osteoporosis Int 18:129\u2013142","journal-title":"Osteoporosis Int"},{"key":"328_CR25","doi-asserted-by":"crossref","first-page":"471","DOI":"10.3928\/0147-7447-19930401-12","volume":"16","author":"G Ross","year":"1993","unstructured":"Ross G, Kuwamura GA (1993) Association of Fabry\u2019s disease with femoral head avascular necrosis. Orthopedics 16:471\u2013473","journal-title":"Orthopedics"},{"key":"328_CR26","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1359\/jbmr.2003.18.11.1947","volume":"18","author":"KL Stone","year":"2003","unstructured":"Stone KL, Seeley DG, Lui L-Y et al (2003) BMD at multiple sites and risk of fracture of multiple types: long-term results from the study of osteoporotic fractures. J Bone Miner Res 18:1947\u20131954","journal-title":"J Bone Miner Res"},{"key":"328_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clineuro.2009.10.011","volume":"112","author":"A Verrotti","year":"2010","unstructured":"Verrotti A, Coppola G, Parisi P, Mohn A, Chiarelli F (2010) Bone and calcium metabolism and antiepileptic drugs. Clin Neurol Neurosur 112:1\u201310","journal-title":"Clin Neurol Neurosur"},{"key":"328_CR28","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1056\/NEJM199102073240607","volume":"324","author":"W Scheidt von","year":"1991","unstructured":"von Scheidt W, Eng CM, Fitzmaurice TF et al (1991) An atypical variant of Fabry\u2019s disease with manifestations confined to the myocardium. N Engl J Med 324:395\u2013399","journal-title":"N Engl J Med"},{"key":"328_CR29","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1016\/S0140-6736(08)61589-5","volume":"372","author":"YA Zarate","year":"2008","unstructured":"Zarate YA, Hopkin RJ (2008) Lysosomal storage disease 3: Fabry\u2019s disease. Lancet 372:1427\u20131435","journal-title":"Lancet"}],"container-title":["JIMD Reports","JIMD Reports, Volume 17"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/8904_2014_328","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T13:48:12Z","timestamp":1649771292000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/8904_2014_328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"ISBN":["9783662445778","9783662445785"],"references-count":29,"URL":"https:\/\/doi.org\/10.1007\/8904_2014_328","relation":{"is-part-of":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1007\/978-3-662-44578-5","asserted-by":"object"}]},"ISSN":["2192-8304","2192-8312"],"issn-type":[{"value":"2192-8304","type":"print"},{"value":"2192-8312","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014]]}}}